Theravance Biopharma, Inc. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
Theravance Biopharma, Inc. (TBPH) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.06 per share for the 3-month period ending 2022-12-31, per its 10-K filed 2024-03-01.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2024-03-01
- Theravance Biopharma, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-12-31 was $0.06, a 82.86% decline year-over-year.
- Theravance Biopharma, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-09-30 was $12.35, a 4310.71% increase year-over-year.
- Theravance Biopharma, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-06-30 was $0.24, a 26.32% increase year-over-year.
- Theravance Biopharma, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-03-31 was $0.21, a 90.91% increase year-over-year.
- Theravance Biopharma, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2022 was $13.11, a 1280.00% increase from fiscal 2021.
- Theravance Biopharma, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2021 was $0.95, a 251.85% increase from fiscal 2020.
- Theravance Biopharma, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2020 was $0.27.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.06 10-K · filed 2024-03-01 | $13.11 10-K · filed 2024-03-01 | ||
| 2022-09-30 | $12.35 10-K · filed 2024-03-01 | $12.70 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.24 10-K · filed 2024-03-01 | $0.38 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $0.21 10-K · filed 2024-03-01 | |||
| 2021-12-31 | $0.35 10-K · filed 2023-03-01 | $0.95 10-K · filed 2023-03-01 | ||
| 2021-09-30 | $0.28 10-K · filed 2023-03-01 | $0.59 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.19 10-K · filed 2023-03-01 | |||
| 2021-03-31 | $0.11 10-K · filed 2023-03-01 | |||
| 2020-12-31 | $0.27 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |